Boston Scientific Corp. Second Quarter Earnings Sneak Peek
S&P 500 (NYSE:SPY) component Boston Scientific Corp. (NYSE:BSX) will unveil its latest earnings on Thursday, July 28, 2011. Boston Scientific, Inc. offers medical devices used in interventional cardiology, cardiac rhythm management, peripheral interventions, endoscopy, gynecology, electrophysiology, neurovascular intervention and neuromodulation.
Boston Scientific Corp. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for net income of 8 cents per share, a rise of 33.3% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged and it has not changed during the last month. For the year, analysts are projecting profit of 40 cents per share, a decline of 16.7% from last year.
Past Earnings Performance: The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by 10 cents, reporting net income of 14 cents per share against a mean estimate of profit of 4 cents per share.
Wall St. Revenue Expectations: On average, analysts predict $1.94 billion in revenue this quarter, a rise of 0.5% from the year ago quarter. Analysts are forecasting total revenue of $7.75 billion for the year, a decline of 0.8% from last year’s revenue of $7.81 billion.
Analyst Ratings: Analysts seem relatively indifferent about Boston Scientific with 18 of 26 analysts surveyed maintaining a hold rating.
Revenue has fallen in the past four quarters. Revenue declined 1.8% to $1.93 billion in first quarter. The figure fell 3.7% in the fourth quarter of the last fiscal year from the year earlier, dropped 5.4% in third quarter of the last fiscal year from the year-ago quarter and 7% in the second quarter of the last fiscal year.
Competitors to Watch: Medtronic, Inc. (NYSE:MDT), St. Jude Medical, Inc. (NYSE:STJ), Merit Medical Systems, Inc. (NASDAQ:MMSI), C.R. Bard, Inc. (NYSE:BCR), Abbott Laboratories (NYSE:ABT), Johnson & Johnson (NYSE:JNJ), Stryker Corporation (NYSE:SYK), Teleflex Incorporated (NYSE:TFX), AngioDynamics, Inc. (NASDAQ:ANGO), and The Spectranetics Corp. (NASDAQ:SPNC).
Stock Price Performance: During May 23, 2011 to July 20, 2011, the stock price had risen 43 cents (6.5%) from $6.57 to $7. The stock price saw one of its best stretches over the last year between March 22, 2011 and March 30, 2011 when shares rose for seven-straight days, rising 6.2% (+43 cents) over that span. It saw one of its worst periods between May 31, 2011 and June 8, 2011 when shares fell for seven-straight days, falling 6.5% (-47 cents) over that span. Shares are down 57 cents (-7.5%) year to date.
(Source: Xignite Financials)